TABLE 1.
Summary of all studies included in the review
| Study [ref.] | Country | Year | Study type | Clinical diagnosis standards (CDS) | CDS year | Measurement instrument | Population characteristics | |||
| Sample size | Male sex | Mean age | Mean FVC% | |||||||
| De Vries et al. [77] | Netherlands | 2000 | Cohort study | NR | NR | SGRQ WHOQOL |
10 | 40 | 61.1 | 79.6 |
| Martinez et al. [43] | Brazil | 2000 | Cross-sectional study | NR | NR | SF36 | 34 | 59 | 52.3 | 62.4 |
| Clark et al. [78] | UK | 2001 | Prospective observational study | ATS/ERS | 2000 | SF36 | 50 | 66 | 67.7 | 80.9 |
| De Vries et al. [31] | Netherlands | 2001 | Cross-sectional study | ATS/ERS | 2000 | WHOQOL | 41 | 37 | 63.5 | NR |
| Baddini et al. [38] | Brazil | 2002 | Cohort study | ATS/ERS | 2000 | SF36 | 30 | 60 | 58.6 | 61.9 |
| Jastrzebski et al. [41] | Poland | 2005 | Cross-sectional study | ATS/ERS | 2000 | SF36 | 16 | 69 | 48.3 | 44.0 |
| Nishiyama et al. [79] | Japan | 2005 | Prospective observational study | ATS/ERS | 2000 | SGRQ | 41 | 85 | 64.0 | 76.6 |
| Tomioka et al. [80] | Japan | 2005 | RCT | ATS/ERS | 2000 | SF36 | 22 | NR | 70.0 | 72.5 |
| Tzanakis et al. [81] | Sweden | 2005 | Cross-sectional study | ATS/ERS | 2000 | SGRQ | 25 | 80 | 66.0 | 68.8 |
| Antoniou et al. [82] | Greece | 2006 | RCT | ATS/ERS | 2000 | SGRQ | 50 | 84 | 66.9 | 71.4 |
| Tomioka et al. [83] | Japan | 2007 | Cross-sectional and longitudinal study | ATS/ERS | 2000 | SF36 | 46 | 70 | 69.9 | 71.0 |
| Zimmermann et al. [84] | Brazil | 2007 | Cross-sectional study | ATS/ERS | 2000 | SGRQ SF36 |
20 | NR | 61.5 | 70.4 |
| Feltrim et al. [39] | Brazil | 2008 | Cross-sectional cohort study | NR | NR | SGRQ | 7 | 57 | 54.1 | NR |
| King et al. [85] | Multi-country | 2008 | RCT (BUILD-1) | ATS/ERS | 2002 | SGRQ SF36 |
154 | 73 | 65.2 | 67.8 |
| Krishnan et al. [86] | USA | 2008 | Cross-sectional study | ATS/ERS | 2000 | SF36 | 39 | 54 | 67.7 | 68.9 |
| Nishiyama et al. [87] | Japan | 2008 | RCT | ATS/ERS | 2000 | SGRQ | 28 | 75 | 66.2 | 67.5 |
| Peng et al. [88] | China | 2008 | Cross-sectional and longitudinal study | ATS/ERS | 2000 | SGRQ | 68 | 64.0 | 66.0 | |
| Raghu et al. [89] | USA | 2008 | RCT | ATS/ERS | 2000 | SGRQ SF36 |
87 | 68 | 65.2 | 63.9 |
| Han et al. [90] | USA | 2009 | Cross-sectional study | ATS/ERS | 2000 | SGRQ SF12 |
221 | 67 | 63.0 | 62.9 |
| IPF Clinical Research Network et al. [91] | USA | 2010 | RCT (STEP-IPF) | ATS/ERS | 2000 | SGRQ EQ5D SF36 |
180 | 83 | 69.0 | 56.8 |
| Jastrzebski et al. [42] | Poland | 2010 | Cross-sectional study | NR | NR | SGRQ SF36 |
30 | 80 | 52.2 | 41.2 |
| Key et al. [92] | UK | 2010 | Cross-sectional study | ATS/ERS | 2002 | LCQ | NR | 74 | 70.8 | 78.5 |
| Lindell et al. [93] | USA | 2010 | Mixed method intervention study | ATS/ERS | 2000 | SF36 | 21 | 76 | 66.2 | NR |
| Lutogniewska et al. [51] | Poland | 2010 | NR | NR | NR | SGRQ SF36 |
30 | NR | NR | NR |
| Ozalevli et al. [94] | Turkey | 2010 | Prospective observational study | ATS/ERS | 2000 | SF36 | 15 | 67 | 62.8 | 71.6 |
| Raghu et al. [95] | Multi-country | 2010 | RCT (BUILD-1) | ATS/ERS | 2000 | SGRQ | 154 | 73 | 65.2 | 67.8 |
| Swigris et al. [74] | USA | 2010 | Cohort study | ATS/ERS | 2000 | ATAQ-IPF | 95 | 82 | 69.3 | 66.0 |
| Swigris et al. [76] | USA | 2010 | RCT (BUILD-1) | ATS/ERS | 2000 | SGRQ SF36 |
100 | 73 | 65.1 | 66.97 |
| du Bois et al. [96] | Multi-country | 2011 | RCT | ATS/ERS | 2000 | SGRQ | 822 | 71 | 66.0 | 72.5 |
| Elfferich et al. [49] | Netherlands | 2011 | Cross-sectional study | other | NR | WHOQOL | 49 | 63 | 63.1 | 82.9 |
| Jones et al. [97] | UK | 2011 | Case control study | ATS/ERS | 2002 | LCQ | NR | 63 | 72.0 | 80.4 |
| King et al. [98] | Multi-country | 2011 | RCT (BUILD-3) | ATS/ERS | 2000 | SF36 EQ5D |
581 | 70 | 63.8 | 74.5 |
| Kozu et al. [99] | Japan | 2011 | Prospective non-randomised open trial | ATS/ERS | 2000 | SF36 | 45 | 82 | 67.5 | 68.6 |
| Kozu et al. [100] | Japan | 2011 | Prospective non-randomised, and uncontrolled study | ATS/ERS | 2000 | SF36 | 65 | 71 | 67.5 | 65.3 |
| Mishra et al. [101] | India | 2011 | RCT | ATS/ERS | 2002 | SGRQ | NR | 100 | 70.7 | 61.4 |
| Rammaert et al. [102] | France | 2011 | Prospective observational study | ATS/ERS | 2000 | SGRQ SF36 |
NR | 62 | 67.1 | 67.0 |
| Swigris et al. [103] | USA | 2011 | Prospective observational study | ATS/ERS | 2000 | SF36 | 21 | 86 | 71.5 | 73.0 |
| Verma et al. [45] | Canada | 2011 | Cross-sectional study | ATS/ERS | 2000 | SGRQ SF36 |
137 | 66 | 59.4 | 61.7 |
| Horton et al. [50] | USA | 2012 | RCT | other | NR | SGRQ CQLQ |
23 | 78 | 67.6 | 70.4 |
| Nishiyama et al. [104] | Japan | 2012 | Retrospective cohort study | ATS/ERS | 2000 | SGRQ | 87 | 89 | 66.3 | 75.0 |
| Noth et al. [105] | USA | 2012 | RCT (ACE-IPF) | ATS/ERS/JRS/ALAT | 2011 | SGRQ EQ5D SF36 |
145 | 73 | 67.0 | 58.8 |
| Raghu et al. [106] | USA | 2012 | RCT (PANTHER-IPF) | ATS/ERS/JRS/ALAT | 2011 | SGRQ SF36 |
155 | 75 | 68.4 | 70.7 |
| Shulgina et al. [107] | UK | 2012 | RCT | ATS/ERS | 2000 | SGRQ EQ5D |
181 | 72 | 71.6 | 70.7 |
| Swigris et al. [108] | USA | 2012 | RCT (STEP-IPF) | ATS/ERS | 2005 | SGRQ SF36 |
180 | 83 | 69.0 | 56.8 |
| Lechtzin et al. [109] | USA | 2013 | RCT | ATS/ERS/JRS/ALAT | 2011 | SGRQ CQLQ |
20 | 75 | 67.6 | 70.4 |
| Mermigkis et al. [110] | Greece | 2013 | Prospective cohort study | ATS/ERS/JRS/ALAT | 2011 | SF36 | 23 | 78 | 68.2 | 76.2 |
| Tzouvelekis et al. [111] | Greece | 2013 | Non-randomised Clinical Trial | ATS/ERS/JRS/ALAT | 2011 | SGRQ | 14 | 86 | 64.4 | 74.2 |
| Alhamad [112] | Saudi Arabia | 2014 | Retrospective cohort study | ATS/ERS/JRS/ALAT | 2011 | SF36 | 58 | 57 | 62.9 | 65.2 |
| Gaunaurd et al. [71] | USA | 2014 | RCT | ATS/ERS/JRS/ALAT | 2011 | SGRQI | 21 | 68.6 | 60.5 | |
| IPF Clinical Research Network et al. [113] | USA | 2014 | RCT (PANTHER-IPF) | ATS/ERS/JRS/ALAT | 2011 | SGRQ EQ5D SF36 |
264 | 78 | 67.7 | 72.8 |
| Kozu et al. [114] | Japan | 2014 | Prospective cross-sectional study | ATS/ERS/JRS/ALAT | 2011 | SF36 | 65 | 71 | 67.5 | 65.3 |
| Lubin et al. [115] | USA | 2014 | Cohort study | ATS/ERS | 2000 | SF36 | 102 | 75 | 70.0 | 70.0 |
| Morsi et al. [33] | Egypt | 2014 | Cross-sectional study | NR | NR | SGRQ | 36 | 22 | 53.0 | 46.3 |
| Richeldi et al. [116] | Multi-country | 2014 | RCT (INPULSIS-1, INPULSIS-2) | ATS/ERS | 2000 | SGRQ | 1061 | 79 | 66.8 | 79.6 |
| Rifaat et al. [34] | Egypt | 2014 | Prospective observational study | ATS/ERS/JRS/ALAT | 2011 | SGRQ | 30 | 27 | 54.4 | 51.9 |
| Vainshelboim et al. [117] | Israel | 2014 | RCT | ATS/ERS/JRS/ALAT | 2011 | SGRQ | 32 | 66 | 67.3 | 68.2 |
| Bors et al. [118] | USA | 2015 | Prospective, cross-sectional study | ATS/ERS/JRS/ALAT | 2011 | SF36 | 46 | 63 | 64.6 | 61.7 |
| Huang et al. [119] | China | 2015 | RCT | ATS/ERS/JRS/ALAT | 2011 | SGRQ | 76 | 93 | 60.3 | 77.3 |
| Mermigkis et al. [120] | Greece | 2015 | Prospective cohort study | ATS/ERS/JRS/ALAT | 2011 | SF36 | 55 | NR | 70.3 | NR |
| Nathan et al. [121] | Multi-country | 2015 | RCT (CAPACITY) | ATS/ERS | 2000 | SGRQ | 338 | 73 | 66.5 | 74.7 |
| Raghu et al. [122] | Multi-country | 2015 | RCT | ATS/ERS | 2000 | SGRQ | 126 | 80 | 65.0 | 67.2 |
| Vainshelboim et al. [123] | Israel | 2015 | RCT | ATS/ERS/JRS/ALAT | 2011 | SGRQ | 28 | 66 | 67.3 | 68.2 |
| Atkins et al. [63] | UK | 2016 | Prospective cohort study | ATS/ERS/JRS/ALAT | 2011 | SGRQ EQ5D KBILD |
77 | 59 | 76.4 | 84.3 |
| Bahmer et al. [124] | Germany | 2016 | Prospective cohort study | ATS/ERS/JRS/ALAT | 2011 | SGRQ SF12 |
41 | 75 | 67.1 | 75.4 |
| Costabel et al. [125] | Multi-country | 2016 | RCT (INPULSIS-1, INPULSIS-2) | ATS/ERS | 2000 | SGRQ | 1061 | 79 | 66.8 | 79.6 |
| Ferrara et al. [61] | Sweden | 2016 | Cross-sectional study | ATS/ERS/JRS/ALAT | 2011 | KBILD | 71 | 70 | 68.3 | 77.5 |
| Hopkins et al. [47] | Canada | 2016 | Retrospective population-based study | ICD | NR | HUI2 | 8295 | 54 | NR | NR |
| Kolb et al. [126] | Multi-country | 2016 | RCT (INPULSIS-1, INPULSIS-2) | ATS/ERS | 2000 | SGRQ | 1081 | 78 | 65.5 | 78.1 |
| Kotecha et al. [127] | UK | 2016 | Cohort study | ATS/ERS/JRS/ALAT | 2011 | SGRQ | 75 | 58 | 76.4 | 83.6 |
| Richeldi et al. [128] | Multi-country | 2016 | RCT (TOMORROW-1, INPULSIS-1, INPULSIS-2) | ATS/ERS | 2000 | SGRQ | 1231 | 79 | 66.5 | 79.7 |
| Taniguchi et al. [129] | Multi-country | 2016 | RCT (INPULSIS-1, INPULSIS-2) | ATS/ERS | 2000 | SGRQ | 322 | 80 | 66.0 | 81.2 |
| Yount et al. [48] | USA | 2016 | Prospective cohort study | Patient referred | NR | ATAQ-IPF PROMIS |
220 | 70 | 61.0 | NR |
| Yu et al. [46] | China | 2016 | RCT | CTS | NR | SGRQ | NR | NR | NR | NR |
| Arizono et al. [130] | Japan | 2017 | Prospective observational study | ATS/ERS | 2002 | SGRQ | 22 | 64 | 70.5 | 72.2 |
| Azuma et al. [131] | Japan | 2017 | RCT (INPULSIS-1, INPULSIS-2) | ATS/ERS | 2000 | SGRQ | 126 | 81 | 68.3 | 81.9 |
| Birring et al. [64] | Multi-country | 2017 | RCT | ATS/ERS/JRS/ALAT | 2011 | KBILD LCQ |
24 | 63 | 67.6 | 73.0 |
| Cheng et al. [132] | Canada | 2017 | Prospective cohort study | ATS/ERS/JRS/ALAT | 2011 | SGRQ | 77 | 69 | 68.7 | 73.2 |
| Collard et al. [133] | Multi-country | 2017 | RCT (INPULSIS-1, INPULSIS-2) | ATS/ERS | 2000 | SGRQ | 1061 | 79 | 66.8 | 79.6 |
| Dowman et al. [52] | Australia | 2017 | RCT | NR | NR | SGRQI | 61 | 67 | 71.4 | 75.9 |
| Furukawa et al. [134] | Japan | 2017 | Retrospective cohort study | ATS/ERS/JRS/ALAT | 2011 | SGRQ | 182 | 85 | 65.6 | 79.7 |
| Glaspole et al. [53] | Australia | 2017 | Observational study | NR | NR | SGRQ | 422 | 67 | 71.3 | 81.0 |
| Koyama et al. [135] | Japan | 2017 | Prospective cohort study | ATS/ERS/JRS/ALAT | 2011 | Bartel Index | 47 | 89 | 75.5 | 75.4 |
| Kreuter et al. [136] | Germany | 2017 | Observational study | ATS/ERS/JRS/ALAT | 2011 | SGRQ EQ5D |
623 | 77 | 69.6 | 67.5 |
| Lee et al. [137] | South Korea | 2017 | Prospective cohort study | ATS/ERS/JRS/ALAT | 2011 | SGRQ | 112 | 84 | 70.0 | 85.0 |
| Magnani et al. [35] | Italy | 2017 | Prospective cohort study | ATS/ERS/JRS/ALAT | 2011 | PGWBI | 18 | 45 | 66.5 | 62.4 |
| Matsuda et al. [138] | Japan | 2017 | Retrospective cohort study | ATS/ERS/JRS/ALAT | 2011 | SGRQ | 121 | 82 | 66.8 | 81.1 |
| Matsuda et al. [139] | Japan | 2017 | Retrospective cohort study | ATS/ERS/JRS/ALAT | 2011 | SGRQ COPD |
106 | 85 | 67.1 | 81.9 |
| Natalini et al. [140] | USA | 2017 | Cross-sectional study | ATS/ERS/JRS/ALAT | 2011 | SF36 | 50 | 78 | 70.8 | 70.3 |
| Root et al. [141] | USA | 2017 | Observational study | ATS/ERS/JRS/ALAT | 2011 | SF36 LCQ |
188 | 56 | 65.8 | 73.9 |
| Sokai et al. [142] | Japan | 2017 | Prospective cohort study | ATS/ERS/JRS/ALAT | 2011 | SGRQ SF36 |
52 | 85 | 72.0 | 86.1 |
| Swigris et al. [143] | Multi-country | 2017 | RCT (TOMORROW-1) | ATS/ERS | 2000 | SGRQ | 426 | 75 | 65.1 | 81.3 |
| Wapenaar et al. [65] | Multi-country | 2017 | Prospective cohort study | ATS/ERS | 2000 | SGRQ KBILD EQ5D |
108 | 78 | 70.5 | 72.5 |
| Atkins et al. [66] | UK | 2018 | Prospective observational study | ATS/ERS/JRS/ALAT | 2011 | KBILD | 39 | 69 | 75.1 | 82.7 |
| Bacci et al. [144] | USA | 2018 | Cross-sectional qualitative study and secondary quantitative analysis of clinical trial data | ATS/ERS/JRS/ALAT | 2011 | SGRQ EQ5D |
30 | 60 | 67.7 | 70.2 |
| Capparelli et al. [70] | Argentina | 2018 | Cohort study- instrument validation | ATS/ERS/JRS/ALAT | 2011 | SGRQI | 23 | 78 | 71.9 | 68.9 |
| da Fontoura et al. [40] | Brazil | 2018 | Retrospective cohort study | NR | SF36 | 31 | 60 | 57.1 | 49.0 | |
| Grufstedt et al. [145] | Sweden | 2018 | Retrospective cohort study | ATS/ERS/JRS/ALAT | 2011 | SGRQ COPD |
87 | 62 | 70.1 | 84.21 |
| Kolb et al. [146] | Multi-country | 2018 | RCT (INSTAGE) | ATS/ERS/JRS/ALAT | 2011 | SGRQ EQ5D |
273 | 79 | 70.2 | 67.0 |
| Mavroudi et al. [147] | Greece | 2018 | Case control study | ATS/ERS | 2000 | SF36 | 19 | 58 | 69.8 | 75.6 |
| Nishiyama et al. [148] | Japan | 2018 | Prospective observational study | ATS/ERS/JRS/ALAT | 2011 | SGRQ | 31 | 74 | 72.3 | 73.8 |
| Nolan et al. [53] | UK | 2018 | Prospective cohort study | ATS/ERS/JRS/ALAT | 2011 | KBILD | 65 | 89 | 72.0 | 73.2 |
| Raghu et al. [149] | USA | 2018 | RCT (WRAP-IPF) | ATS/ERS/JRS/ALAT | 2011 | SGRQ | 58 | 82 | 69.9 | 75.4 |
| Rajala et al. [150] | Finland | 2018 | Prospective observational study | ATS/ERS/JRS/ALAT | 2011/2015 | RAND36 | 92 | 73 | 75.0 | 78.0 |
| Rosas et al. [151] | USA | 2018 | RCT | ATS/ERS/JRS/ALAT | 2011 | SGRQ | 58 | 81 | 67.6 | 71.1 |
| Swigris et al. [152] | Multi-country | 2018 | RCT (INPULSIS-1, INPULSIS-2) | ATS/ERS | 2000 | SGRQ EQ5D |
1081 | 79 | 66.8 | 79.6 |
| Szentes et al. [54] | Germany | 2018 | Prospective observational study | NR | NR | KBILD EQ5D |
268 | 86 | 63.2 | 77.4 |
| Takeda et al. [153] | Japan | 2018 | Prospective cohort study | ATS/ERS/JRS/ALAT | 2015 | COPD | 25 | 84 | 74.4 | 80.6 |
| Vancheri et al. [154] | Multi-country | 2018 | RCT (INJOURNEY) | ATS/ERS/JRS/ALAT | 2011 | EQ5D | 104 | 86 | 68.9 | 84.0 |
| Wuyts et al. [155] | Multi-country | 2018 | Prospective observational study | ATS/ERS/JRS/ALAT | 2011 | SGRQ EQ5D |
277 | 77 | 69.6 | 80.6 |
| Bosi et al. [156] | Italy | 2019 | Prospective observational study | ATS/ERS/JRS/ALAT | 2011 | SGRQ | 47 | 76 | 68.7 | 75.5 |
| Chehere et al. [157] | France | 2019 | Prospective cohort study | ATS/ERS | 2001 | SF36 | 19 | 75 | 65.0 | 75.0 |
| Eken et al. [158] | Turkey | 2019 | Cross-sectional study | ATS/ERS/JRS/ALAT | 2011 | SGRQ | 40 | 78 | 65.5 | 86.6 |
| Justice et al. [159] | USA | 2019 | RCT | ATS/ERS/JRS/ALAT | 2011 | SGRQ | 14 | 88 | 70.8 | NR |
| Kalafatis et al. [69] | Sweden | 2019 | Observational study | ATS/ERS/JRS/ALAT | 2011 | KBILD | 348 | 72 | 72.0 | 70.2 |
| Kimman et al. [57] | Netherlands | 2019 | Prospective cohort study | NR | NR | PESaM EQ5D |
188 | 76 | 69 | NR |
| Kreuter et al. [55] | Germany | 2019 | Observational study | NR | NR | SGRQ EQ5D |
424 | 77 | 68.7 | 36.1 |
| Nolan et al. [56] | UK | 2019 | Prospective cohort study | NR | NR | KBILD | 209 | 61 | 70.0 | 71.9 |
| Pan et al. [44] | China | 2019 | Cross-sectional study | ATS/ERS/JRS/ALAT | 2011 | SGRQ ATAQ-IPF |
20 | 70 | 58.3 | NR |
| Prior et al. [73] | Denmark | 2019 | Prospective cohort study | ATS/ERS/JRS/ALAT | 2011 | SGRQI SGRQ KBILD |
150 | 81 | 72.9 | 87.2 |
| Ryerson et al. [160] | Multi-country | 2019 | RCT (INPULSIS-1, INPULSIS-2) | ATS/ERS | 2000 | SGRQ | 1060 | 79 | 66.8 | 79.6 |
| Sinha et al. [36] | UK | 2019 | Prospective cohort study | NR | NR | KBILD | 57 | 33 | 62.0 | 80.0 |
| Wallaert et al. [161] | France | 2019 | Prospective cohort study | ATS/ERS/JRS/ALAT | 2011 | VSRQ | 61 | 75 | 66.8 | 68.6 |
| Witt et al. [162] | Multi-country | 2019 | Prospective observational study | ATS/ERS/JRS/ALAT | 2011 | SF36 | 258 | 73 | 67.3 | 62.7 |
| Xu et al. [163] | China | 2019 | RCT (INPULSIS-1, INPULSIS-2) | ATS/ERS | 2000 | SGRQ | 101 | 54 | 64.3 | 80.8 |
| Yuen et al. [164] | USA | 2019 | RCT | ATS/ERS/JRS/ALAT | 2011 | SGRQ | 20 | 65 | 69.8 | 66.0 |
| Bloem et al. [37] | Netherlands | 2020 | Cross-sectional study | ATS/ERS/JRS/ALAT | 2011 | EQ5D QoL-RIQ |
59 | 45 | 73.0 | 83.2 |
| Case et al. [165] | USA | 2020 | Retrospective cohort study | ATS/ERS/JRS/ALAT | 2011 | SGRQ EQ5D SF12 |
662 | 75 | 70.0 | 69.9 |
| Janssen et al. [166] | USA | 2020 | RCT | ATS/ERS/JRS/ALAT | 2011 | SGRQ | 22 | 71 | 90.9 | 73.4 |
| Kreuter et al. [167] | Multi-country | 2020 | RCT (INPULSIS-1, INPULSIS-2) | ATS/ERS | 2000 | SGRQ | 1061 | 79 | 66.8 | 79.6 |
| Moor et al. [67] | Netherlands | 2020 | RCT | ATS/ERS/JRS/ALAT | 2018 | PESaM EQ5D KBILD |
90 | 91 | 71.0 | 80.1 |
| O'Brien et al. [168] | USA | 2020 | Cross-sectional study | ATS/ERS/JRS/ALAT | 2011 | SGRQ EQ5D SF12 |
859 | 74 | 70.0 | 69.7 |
| Prior et al. [72] | Denmark | 2020 | Prospective cohort study | ATS/ERS/JRS/ALAT | 2011 | SGRQI SGRQ KBILD |
150 | 81 | 72.9 | 87.2 |
| Richeldi et al. [169] | Multi-country | 2020 | RCT (INPULSIS-1, INPULSIS-2, INSTAGE) | ATS/ERS ATS/ERS/JRS/ALAT |
2000 2011 |
SGRQ | 1197 | 79 | 67.1 | 78.0 |
| Tzouvelekis et al. [68] | Greece | 2020 | Prospective cohort study | ATS/ERS/JRS/ALAT | 2011 | SGRQ KBILD |
98 | 83 | 70.8 | 77.0 |
All means are calculated pooled means. ACE-IPF: Anti-Coagulant Effectiveness in Idiopathic Pulmonary Fibrosis; ATS/ERS: American Thoracic Society/European Respiratory Society; ATS/ERS/JRS/ALAT: American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Society; ATAQ-IPF: A Tool to Assess Quality of life in IPF; BUILD: Bosentan Use in Interstitial Lung Disease; CQLQ: The Cough Quality of Life Questionnaire; CTS: Chinese Thoracic Society; EQ5D: EuroQol; FVC: Forced vital capacity; HUI2: Health Utilities Index Mark 2; IPF: idiopathic pulmonary fibrosis; K-BILD: King's Brief Interstitial Lung Disease; LCQ: Leicester Cough Questionnaire; NR: not reported; PANTHER Prednisone, Azathioprine, and N-acetylcysteine in Participants With IPF; PESaM: Patient Experiences and Satisfaction with Medications Questionnaire; PGWBI: The Psychological General Well-Being Index; PROMIS: Participant Reported Outcomes Measurement Information System; QoL-RIQ: Quality-of-Life for Respiratory Illness; RAND36: Research and Development 36 item health survey; RCT: Randomised controlled trial; SF12: Short Form-12; SF36 Short Form-36; SGRQ: St George's Questionnaire; SGRQI: IPF-specific version of the SGRQ; STEP-IPF: Sildenafil Trial Of Exercise Performance In Idiopathic Pulmonary Fibrosis; VSRQ: Visual Simplified Respiratory Questionnaire; WHOQoL: WHO Quality of Life Questionnaire; WRAP-IPF: Treatment of IPF With Laparoscopic Anti-Reflux Surgery.